> Detailanzeige

Ewert, Annika; Leifheit-Nestler, Maren; Hohenfellner, Katharina; Büscher, Anja; Kemper, Markus J; Oh, Jun; Billing, Heiko; Thumfart, Julia; Stangl, Gabriele; Baur, Anja C; Föller, Michael; Feger, Martina; Weber, Lutz T; Acham-Roschitz, Birgit; Arbeiter, Klaus; Tönshoff, Burkhard; Zivicnjak, Miroslav; Haffner, Dieter

Bone and Mineral Metabolism in Children with Nephropathic Cystinosis Compared with other CKD Entities

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Bone and Mineral Metabolism in Children with Nephropathic Cystinosis Compared with other CKD Entities
  • Beteiligte: Ewert, Annika; Leifheit-Nestler, Maren; Hohenfellner, Katharina; Büscher, Anja; Kemper, Markus J; Oh, Jun; Billing, Heiko; Thumfart, Julia; Stangl, Gabriele; Baur, Anja C; Föller, Michael; Feger, Martina; Weber, Lutz T; Acham-Roschitz, Birgit; Arbeiter, Klaus; Tönshoff, Burkhard; Zivicnjak, Miroslav; Haffner, Dieter
  • Erschienen: The Endocrine Society, 2020
  • Erschienen in: The Journal of Clinical Endocrinology & Metabolism, 105 (2020) 8, Seite e2738-e2752
  • Sprache: Englisch
  • DOI: 10.1210/clinem/dgaa267
  • ISSN: 0021-972X; 1945-7197
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Abstract Context Children with nephropathic cystinosis (NC) show persistent hypophosphatemia, due to Fanconi syndrome, as well as mineral and bone disorders related to chronic kidney disease (CKD); however, systematic analyses are lacking. Objective To compare biochemical parameters of bone and mineral metabolism between children with NC and controls across all stages of CKD. Design Cross-sectional multicenter study. Setting Hospital clinics. Patients Forty-nine children with NC, 80 CKD controls of the same age and CKD stage. Main outcome measures Fibroblast growth factor 23 (FGF23), soluble Klotho, bone alkaline phosphatase (BAP), tartrate-resistant acid phosphatase 5b (TRAP5b), sclerostin, osteoprotegerin (OPG), biochemical parameters related to mineral metabolism, and skeletal comorbidity. Results Despite Fanconi syndrome medication, NC patients showed an 11-fold increased risk of short stature, bone deformities, and/or requirement for skeletal surgery compared with CKD controls. This was associated with a higher frequency of risk factors such as hypophosphatemia, hypocalcemia, low parathyroid hormone (PTH), metabolic acidosis, and a specific CKD stage-dependent pattern of bone marker alterations. Pretransplant NC patients in mild to moderate CKD showed a delayed increase or lacked an increase in FGF23 and sclerostin, and increased BAP, TRAP5b, and OPG concentrations compared with CKD controls. Post-transplant, BAP and OPG returned to normal, TRAP5b further increased, whereas FGF23 and PTH were less elevated compared with CKD controls and associated with higher serum phosphate. Conclusions Patients with NC show more severe skeletal comorbidity associated with distinct CKD stage-dependent alterations of bone metabolism than CKD controls, suggesting impaired mineralization and increased bone resorption, which is only partially normalized after renal transplantation.
  • Zugangsstatus: Freier Zugang